Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib with FOLFIRI versus masitinib alone versus best supportive care in metastatic colorectal cancer
2013-000493-30Phase 2Terminated
- Sponsor
- AB Science
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of masitinib in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by AB Science. Primary endpoint: Overall survival. Started Dec 2014; status: terminated.
02
Drugs
masitinib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2013-000493-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000493-30.